


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

PATENT  
Attorney Docket No.: 015280-271100US  
Client Reference No.: E-01/04/



RECEIVED

DEC 19 2003

TECH CENTER 1600/2900

On DECEMBER 10, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: *Kimberly Rana*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Gonzalez, Frank J. et al.

Application No.: 09/308,080

Filed: October 28, 1999

For: METHODS AND COMPOSITIONS  
FOR DETECTING  
DIHYDROPYRIMIDINE  
DEHYDROGENASE SPLICING  
MUTATIONS

Examiner: Ramirez, Delia M.

Art Unit: 1652

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR §1.97 and §1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.


Respectfully submitted,



Frank J. Mycroft  
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 925-472-5000  
Fax: 925-472-8895  
FJM:mrsv





<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/308,080		
		Filing Date	October 28, 1999		
		First Named Inventor	Gonzales, Ph.D., Frank		
		Art Unit	1652		
		Examiner Name	Ramirez, Delia M.		
Sheet	2	of	2	Attorney Docket Number	015280-271100US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	2	KUILENBURG, Andre B.P. et al.: "Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD Deficiency"; <u>Clinical Cancer Research</u> , Vol. 7; pp. 1149-1153; May 2001	
	3	KUIVANIEMI, Helena et al.: "Identical G+1 to A mutations in three different introns of the Type III procollagen gene (COL3A1) produce different patterns of RNA splicing in three variants of Ehlers-Danlos Syndrome IV"; <u>J. Biological Chemistry</u> , Vol. 265, No. 20; pp. 12067-12074; July 15, 1990	
	4	YOKOTA, Hiroshi et al.: "cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, and enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria"; <u>J. Biological Chemistry</u> , Vol. 269, No. 37; pp. 23192-23196; September 16, 1994	
	5	OMIM Entry for "Dihydropyrimidine Dehydrogenase; DPYD" printed on December 3, 2003; <a href="http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=274270">http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=274270</a> ; 10 pages	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.